{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-054264","form_type":"8-K","ticker":"TLSI","cik":"0001826667","company_name":"TriSalus Life Sciences, Inc.","filed_at":"2026-08-06T20:01:56+00:00","discovered_at":"2026-08-06T20:03:01.321603+00:00","generated_at":"2026-08-06T20:03:19.984485+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"TriSalus Q2 revenue $11.4M (+1.7% YoY); maintains FY2026 guidance $54-57M","bullets":["Revenue from TriNav system $11.4M, up 1.7% YoY; gross margin improved to 86.8% from 83.9%.","Operating loss widened to $9.8M from $7.3M YoY on higher sales and marketing spend.","Net loss $9.2M ($0.16 loss per share) vs $9.0M ($0.27 loss per share) in Q2 2025.","Cash and equivalents $46.3M after $46.0M equity offering in Q1; runway sufficient for expansion.","CMS established G-code for reimbursement of pressure-generating catheter in office-based labs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-054264","json":"https://secwatch.observer/filing/0001628280-26-054264.json","markdown":"https://secwatch.observer/filing/0001628280-26-054264.md","text":"https://secwatch.observer/filing/0001628280-26-054264.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026054264/0001628280-26-054264-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826667/000162828026054264/tlsi-20260806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-06T20:03:19.984485+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}